Net Loss Per Share (Tables)

11 Months Ended

Dec. 31, 2024

Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders

Basic and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):

	Period from February 6, 2024 (Inception) to December 31, 2024
	Loss Allocation			Weighted Average Shares Outstanding		Loss Per Share, Basic and Diluted
Common Stock	$	(65,037	)		16,789,362	$	(3.87	)
Company Series A Preferred Stock ⁽¹⁾		(1,918	)		495	$	(3,873.25	)
Company Series B Preferred Stock ⁽²⁾		(16,769	)		51,946	$	(322.81	)
Net loss	$	(83,724	)

(1)	The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.

(2)	The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the period from February 6, 2024 (inception) to December 31, 2024.

Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share

The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would have had an anti-dilutive effect were as follows:

	December 31, 2024
Outstanding employee warrants to purchase common stock		3,054,358
Outstanding unvested restricted stock awards		2,207,553
Outstanding and issued common stock options		1,567,760
Outstanding and issued warrant to Paruka		596,930
Total		7,426,601

Oruka Therapeutics, Inc. 10-K